tradingkey.logo

Iovance Announces Five-Year Results Of Amtagvi® (Lifileucel) In Patients With Advanced Melanoma At Asco Annual Meeting

ReutersMay 22, 2025 9:32 PM

Iovance Biotherapeutics Inc IOVA.O:

  • IOVANCE ANNOUNCES FIVE-YEAR RESULTS OF AMTAGVI® (LIFILEUCEL) IN PATIENTS WITH ADVANCED MELANOMA AT ASCO ANNUAL MEETING

  • IOVANCE BIOTHERAPEUTICS INC: ONE-TIME AMTAGVI TREATMENT DEMONSTRATED DURABLE RESPONSES AND A FIVE-YEAR OVERALL SURVIVAL RATE OF 20%

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI